Introduction {#s1}
============

Glioblastoma multiforme (GBM) is the most common and malignant form of primary brain tumor ([@B26]; [@B47]). Despite recent advances in surgical and other therapeutic techniques, the median survival of patients with GBM is as low as 12 to 15 months ([@B30]; [@B40]). Aside from the conventional therapies, the selective induction of apoptosis in target cancer cells with pro-apoptotic cytokines, such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) ([@B38]) seems promising, as this strategy exhibited low toxicity to non-cancerous cells, including brain cells, in clinical trials ([@B48]). However, the use of TRAIL is controversial because it is thought to induce apoptosis not only in cultured normal human hepatocytes but also in normal brain tissues ([@B28]). Therefore, the applicability of TRAIL for the treatment of brain cancer by combinatorial drug treatment strategies should be carefully monitored to improve its therapeutic efficacy ([@B48]).

One of the hallmarks and causes of GBM complexity is cellular heterogeneity, which poses a challenge for disease diagnosis and treatment ([@B21]; [@B27]). The molecular profiling of The Cancer Genome Atlas (TCGA) divides GBM into four distinctive subtypes, namely, classical, neural, proneural, and mesenchymal ([@B54]). Both classical and mesenchymal subtypes are aggressive in nature. Whereas the classical subtype is characterized by overexpression of epidermal growth factor receptor (EGFR), the mesenchymal subtype shows decreased neurofibromin 1 (NF1) expression and high transforming growth factor-β (TGF-β) and nuclear factor-κB (NF-κB) activities. The neural subtype is controversial because it is thought to originate from the substantial contamination of GBM samples with healthy brain tissue. Tumorigenesis of the proneural subtype starts from the frontal cortex of the cerebrum and often displays amplification of platelet-derived growth factor receptor α (PDGFRα) and mutations of isocitrate dehydrogenase 1/2 (IDH1/2) and tumor protein 53 (TP53) ([@B54]). Patients with proneural subtype exhibit the best prognosis but may have the worst disease outcomes in the absence of *IDH1* mutations ([@B43]; [@B54]; [@B1]). Although several efforts have been directed to identify the critical driver pathways and therapeutic targets specific for each GBM subtype, very little progress has been made in this direction. A recent report revealed increased sensitivity of patients with proneural GBM to cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment ([@B35]) and significantly faster recurrence after bevacizumab treatment in patients with classic GBM ([@B25]), indicating the importance of careful evaluation of the subtypes before treatment.

The mu-2-related death-inducing gene (MUDENG, *MuD*), also called as the adaptor-related protein complex 5 subunit Mu 1 (AP5M1), was identified as a putative component of the fifth adaptor protein (AP) complex involved in endosomal transport ([@B23]). *MuD* was reported to be involved in the apoptotic pathway in HeLa ([@B34]), Jurkat ([@B34]; [@B46]), and B-JAB ([@B34]) cell lines. Subsequent studies demonstrated the cleavage of MuD by active caspase-3 during TRAIL-induced apoptotic signaling ([@B46]), and the subsequent activation of the anti-apoptotic function of MuD near the BH3-interacting domain death agonist (BID) and B-cell lymphoma 2 (Bcl2) junction ([@B12]). These studies suggest a possible role for MuD in cancer cells apoptotic signaling.

In the present study, we used UALCAN and GEPIA, two web-based tools that allow in-depth analyses of RNA-sequencing data from TCGA database to assess *MuD* expression in cancer cohorts. In addition, we used the microarray data from the Gene Expression Omnibus (GEO) database to validate the selected results. We conducted an integrated analysis using 12 human brain tumor samples and GBM cancer cell lines. Furthermore, we identified the differential expression of *MuD* in tumors as well as the correlation between *MuD* expression and survival in cancer types, including specific GBM subtypes. We also identified the candidate interacting genes that were validated in GBM cell lines.

Materials and Methods {#s2}
=====================

Data Sources {#s2_1}
------------

The TCGA database curated by the National Institute of Health (NIH) comprises 2.5 petabytes of data on cohorts from 33 different tumor types, including genomic profiles from microarrays and next-generation sequencing (NGS) ([@B53]). MET500 is a database of NGS data from 500 patients with cancers of 30 primary sites ([@B45]). Genotype-tissue expression project (GTEx) is a database of NGS and includes the microarray data collected from nearly 1,000 individuals ([@B14]). As test sets, we used data sets available from the GEO database ([@B13]). E-GEOD-53757 ([@B55]) and E-GEOD-22541 ([@B58]) was used for KIRC validation ([@B58]), E-GEOD-70951 ([@B44]) and E-GEOD-10886 ([@B41]) for BRCA validation, E-GEOD-68465 ([@B18]) for LUAD validation and E-GEOD-23400 ([@B49]) for ESCA.

Statistical Analysis {#s2_2}
--------------------

Analysis of the TCGA data was carried out with UALCAN (RRID: SCR_015827) ([@B7]), and GEPIA ([@B51]). The differential expression of *MuD* and patient survival were analyzed with PanCan analysis and expression on box plot, respectively. Cox proportional hazard analysis was performed with GBM-BioDP provided at the Glioblastoma Bio Discovery Portal (<https://gbm-biodp.nci.nih.gov/>) ([@B6]). Patients were divided based on the diagnosed GBM subtype and further stratified into four quartiles as per *MuD* expression level. For each group, a Cox proportional hazard model was used to plot the survival of the patients from the first quartile versus those from the fourth quartile using age and O-6-methylguanine-DNA methyltransferase (*MGMT*) methylation status as covariates. The microarray data from E-GEOD-53757 and E-GEOD-070951 processed with MAS.5 and limma (RRID : SCR_010943) in R, respectively, were visualized as heat maps using ClustVis (<https://biit.cs.ut.ee/clustvis/>) ([@B39]). Heat maps were row-centered and unit variance scaling was applied for rows. Principal components were calculated using the NIPALS PCA method included in pcaMethods R package, and heatmaps were plotted using heatmap R package (version 0.7.7). Differential expression and survival plots were plotted using survminer R package (version 0.4.4) after processing with limma package and z-score (value-mean normal value/normal SD) calculated by R. Student's *t*-test was used to analyze differences between groups in the real-time quantitative polymerase chain reaction (RT-qPCR) and immunoblot data.

Sample Collection From Human Brain Tumors {#s2_3}
-----------------------------------------

This study was approved by the Konkuk University Institutional Review Board (IRB; 7001355-124 201512-E-041), and all patients signed IRB-approved consent forms. The biospecimens used in the present study were provided by the Ajou Human Bio-Resource Bank (Suwon, Korea), a member of the National Biobank of Korea, supported by the Ministry of Health and Welfare. All samples derived from the National Biobank of Korea were obtained with informed consent under institutional review board-approved protocols. We obtained 12 tissues from the following patients ([**Table 1**](#T1){ref-type="table"}): 10 patients diagnosed with glioblastoma grade IV, and healthy tissues of six of these patients; one patient diagnosed with oligodendroglioma grade II; and one patient diagnosed with ependymoma grade II. Samples were stored below −80°C until nucleic acid and protein extraction.

###### 

Differential *MuD* expression and survival correlation revealed by UALCAN and GEPIA.

                 Project name                                      UALCAN        GEPIA         GR(U)   GRG)   S (U)   S (G)
  -------------- ------------------------------------------------- ------------- ------------- ------- ------ ------- -------
  BRCA           Breast invasive carcinoma                         N (n = 114)   N (n = 291)   NS      NS     C       No
  T (n = 1094)   T (n = 1085)                                      (HL)                                               
  CHOL           Cholengiocarcinoma                                N (n = 9)     N (n = 9)     Up      NS     No      No
  T (n = 36)     T (n = 36)                                                                                           
  COAD           Colon adenocarcinoma                              N (n = 41)    N (n = 349)   Down    NS     No      No
  T (n = 286)    T (n = 275)                                                                                          
  DLBC           Lymphoid neoplasm diffuse large B-cell lymphoma   --            N (n = 337)   --      Up     No      No
  T (n = 47)                                                                                                          
  ESCA           Esophageal carcinoma                              N (n = 11)    N (n = 286)   Up      Up     No      No
  T (n = 184)    T (n = 182)                                                                                          
  GBM            Glioblastoma multiforme                           N (n = 5)     N (n = 207)   --      Up     No      No
  T (n = 156)    T (n = 163)                                                                                          
  KICH           Kidney chromophobe                                N (n = 25)    N (n = 53)    NS      Up     No      No
  T (n = 67)     T (n = 66)                                                                                           
  KIRC           Kidney renal clear cell carcinoma                 N (n = 72)    N (n = 100)   Down    Down   .C      C
  T (n = 533)    T (n = 523)                                       (HH)          (HH)                                 
  KIRP           Kidney renal papillary cell carcinoma             N (n = 32)    N (n = 60)    Down    NS     No      No
  T (n = 290)    T (n = 286)                                                                                          
  LGG            Lower-grade glioma                                N (n = 248)   N (n = 207)   NS      Up     No      No
  T (n = 265)    T (n = 518)                                                                                          
  LUAD           Lung adenocarcinoma                               N (n = 29)    N (n = 347)   NS      NS     C       No
  T (n = 519)    T (n = 483)                                       (HL)                                               
  OV             Ovarian serous cystadenocarcinoma                 --            N (n = 88)    --      Up     No      No
  T (n = 426)                                                                                                         
  PAAD           Pancreatic Adenocarcinoma                         N (n = 4)     N (n = 171)   NS      Up     No      No
  T (n = 178)    T (n = 179)                                                                                          
  READ           Rectum adenocarcinoma                             N (n = 11)    N (n = 92)    Down    NS     No      No
  T (n = 166)    T (n = 318)                                                                                          
  STAD           Stomach adenocarcinoma                            N (n = 34)    N (n = 34)    NS      Up     No      No
  T (n = 415)    T (n = 415)                                                                                          
  THYM           Thymoma                                           N (n = 2)     N (n = 339)   NS      Up     No      No
  T (n = 120)    T (n = 118)                                                                                          

Abbreviations of cancer types based on TCGA are given in the left column with project name. UALCAN and GEPIA sample sizes for normal (N) and tumor (T) tissues are indicated for comparison as available or excluded if normal tissue data were unavailable. Gene regulation (GR) upon detection was listed as Up or Down as relevant and according to UALCAN (U) and GEPIA (G). Survival (S) correlation with expression is listed as correlating (C). High expression = Low survival chance (HL) and High expression = High survival chance (HH).

Cell Lines and Cell Culture {#s2_4}
---------------------------

The U251-MG cell line (NCI-DTP Cat U-251, RRID: CVCL 0021) was obtained from Dr Benveniste EN (University of Alabama at Birmingham, Birmingham, AL, USA). The U251-MG *MuD* knock-out (KO) line β18 was generated using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 plasmid SpCas9-2A-puro (PX459) V 2.0 provided by Feng Zhang (RRID: Addgene_6288) and single guide RNA 5′-ACACTAATTAGTGGCGGACG-3′ designed with CRISPR DESIGN (<http://crispr.mit.edu/>). U251-MG cells stably expressing (SE) GFP alone (C1) and GFP-MuD (C1MuD) were generated by transfection using Lipofectamine 2000 and subsequently selected with G418 sulfate (200 µg/ml; Invitrogen, USA). The cells were maintained in minimum essential media (MEM; Gibco, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin (Welgene, Daegu, Korea). All cell lines were cultivated at 37°C in a humid 5% CO~2~ chamber and subcultured every 3 days after they reached 80% to 90% confluency. The cells were not subcultured beyond 20 passages.

RT-qPCR Analysis {#s2_5}
----------------

RNA and proteins were extracted using Nucleospin^®^ RNA/Protein (Macherey-Nagel, BMS, Korea) according to the manufacturer's instructions. cDNA was synthesized using AccuPower^®^ RT/PCR PreMix (Bioneer, Korea). qPCR was performed with SYBR qPCR Mix (CellSafe, Yongin, Korea) on a CFX96 Real-Time System (Bio-Rad, BMS, Korea). Data were analyzed with the Pfaffl method ([@B42]) using glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) gene as reference.

Immunoblot Analysis {#s2_6}
-------------------

Sample lysates were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis, and the separated bands were transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% non-fat milk and incubated with MuD monoclonal antibody ([@B56]) at 4°C overnight. The blots were subsequently incubated with a horseradish peroxidase (HRP)-labeled anti-human IgG at room temperature (15--20°C) for 2 h. The immunoreactive bands were detected with an enhanced chemiluminescence substrate (Dogen, Seoul, Korea), and band intensities were measured with ImageJ. All primers and antibodies used are listed in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

Results {#s3}
=======

Differential Expression of *MuD* in 14 Cancers Types {#s3_1}
----------------------------------------------------

Our previous study suggested the involvement of *MuD* gene in the apoptotic pathway of the GBM cell line U251-MG induced by TRAIL ([@B12]). To investigate the role of *MuD* in cancer, we analyzed *MuD* expression data from the TCGA database ([@B5]), which included 35 different cancer types with normalized RNA expression for 33,096 cases as of December 2018. The analysis was performed with UALCAN, a web-based tool that facilitates in-depth analysis of the TCGA, and MET500 transcriptome databases ([@B7]) and GEPIA, which use the TCGA and GTEx projects databases to compare gene expression between tumor and normal tissues ([@B51]). Differential regulation of *MuD* gene expression was detected in six cancer types with UALCAN and 10 cancer types using GEPIA for a total of 14 cancer types. In most cases, the sample size was larger in the GEPIA database than in UALCAN. *MuD* expression in tumors was upregulated as compared with that in normal tissues in 9 of the 10 cancer types identified by GEPIA versus only two of the eight cancer types identified with UALCAN. *MuD* expression was downregulated only in kidney renal clear cell carcinoma (KIRC) tumor tissues, as per GEPIA analysis, but three additional cancer types were identified with UALCAN. Both of these tools detected *MuD* upregulation in the tumor tissues from patients with esophageal carcinoma (ESCA) and downregulation in patients with KIRC ([**Table 1**](#T1){ref-type="table"}). To validate if tumor purity of the TCGA tumors might affect the outcome, consensus measurement of purity (CPE) as previously described ([@B2]) was used to select GBM and KIRC-TCGA tumor \>0.9 and 0.7 based on tumor purity distribution of the samples. Results consent with UALCAN results, suggesting that divergent result from UALCAN and GEPIA is not due to TCGA tumor quality ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}).

Validation Using Test Data Sets {#s3_2}
-------------------------------

As mentioned above, both tools revealed downregulation of *MuD* in KIRC tumor tissues but failed to detect any significant dysregulation in breast invasive carcinoma. To validate these findings, we selected two test sets from EMBL-EBI ArrayExpress database. Microarray data of patients with renal clear cell carcinoma (E-GEOD-53757) and breast adenocarcinoma (E-GEOD-70951) as control were analyzed. Except for two tumor samples, all tissues from patients with renal cancer showed significantly downregulated *MuD* expression levels relative to the matched normal tissues ([**Figure 1A**](#f1){ref-type="fig"}). In contrast, *MuD* expression in the control data set was differently regulated in tumor tissue as compared with normal tissue ([**Figure 1B**](#f1){ref-type="fig"}), indicative of the absence of any correlation between *MuD* expression and tumor identity. According to both portal, ESCA was up-regulated in tumor. This was validated using E-GEOD-23400 ([**Supplementary Figure 2**](#SM1){ref-type="supplementary-material"}).

![Heatmap showing the expression of *MuD* from microarray data. *MuD* expression in kidney renal clear cell carcinoma **(A)** and adjacent kidney tissue as well as in breast cancer **(B)** and adjacent breast tissue. Clustering was performed with ClustVis using NIPALS PCA method. Red--white--blue scale was used to depict the normalized expression level. Red, blue, green, and violet color bars were used in clear cell renal carcinoma to represent classified stages, whereas red and blue bars were used in breast cancer to represent the diagnosis type.](fgene-10-00884-g001){#f1}

*MuD* Expression Patterns Correlated With Survival in Three Different Cancer Types Based on TCGA Database {#s3_3}
---------------------------------------------------------------------------------------------------------

We investigated the correlation between *MuD* expression and patient survival in selected TCGA cohorts. Kaplan-Meier survival curves were generated using UALCAN for three cancer types based on the information in the TCGA database ([**Figure 2**](#f2){ref-type="fig"}). UALCAN use statistical analysis that divided patients into two groups, comparing the higher quartile to the rest based on *MuD* expression. Among patients with invasive breast cancer (BRCA), those with high *MuD* expression (n = 271) revealed significantly lower survival (*p* \< 0.005) than the controls (n = 810). In LUAD, a similar pattern was observed in the cohort characterized with high MuD expression (n = 128) relative to the corresponding controls (n = 374) (*p* \< 0.05). In KIRC, survival was significantly lower in the cohort with high MuD expression (n = 134) (*p* \< 0.0001) than in controls (n = 397) ([**Figures 2A, B, and C**](#f2){ref-type="fig"} left plot). However, when equal number of samples were used to analyze survival chance, both BRCA and LUAD-TGCA lost their significance (p \> 0.1) ([**Figures 2A, B, and C**](#f2){ref-type="fig"}, middle plot). Validation using E-GEOD data shows that BRCA and LUAD outcomes from TCGA database are divergent from testing data set. Although KIRC data from E-GEOD-22514 lack vital status needed to analyze survival, this can be interfered from data of months free of tumor and total follow-up months as previously tested([@B8]). Although *p* value was high due to the small numbers of samples, higher MuD expression correlated with higher survival, as it was for TCGA data ([**Figure 2C**](#f2){ref-type="fig"}). Therefore, validation shows that although UALCAN is more sensitive in detecting potential correlation between expression and survival, GEPIA give a more robust outcome, possibly due to the fact that UALCAN analyze survival with unbalanced numbers of samples.

![Kaplan-Meier survival curves in TCGA cohorts and E-GEOD data sets. Survival curves based on MuD expression was plotted for breast invasive carcinoma (BRIA) **(A)**, lung adenocarcinoma (LUAD) **(B)**, and kidney renal clear cell carcinoma (KIRC) **(C)**.](fgene-10-00884-g002){#f2}

*MuD* Expression Pattern Correlated With High Survival in Proneural GBM Subtypes and Low Survival in Classical GBM Subtypes {#s3_4}
---------------------------------------------------------------------------------------------------------------------------

Differential gene regulation in GBM tissues was detected with GEPIA but not UALCAN ([**Table 1**](#T1){ref-type="table"} and [**Supplementary Figure 3**](#SM1){ref-type="supplementary-material"}). As patients with GBM can be divided into subtypes with distinct molecular characteristics ([@B54]), we examined the survival of patients with different subtypes based on *MuD* expression. We analyzed 422 GBM samples available from TCGA. Patients were divided based on GBM subtype and further stratified into four quartiles based on *MuD* expression levels. For each subgroup, the Cox proportional hazard model was used to plot the survival of patients in the first quartile versus those in the fourth quartile, with age and *MGMT* methylation status as covariates ([**Figure 3**](#f3){ref-type="fig"}). Interestingly, patients with proneural GBM from the fourth quartile showed significantly higher survival (*p* \< 0.005), with a log-rank *p* \< 0.005 and a hazard ratio (HR) value less than 1 (HR = 0.182). The age HR was slightly higher than 1 (HR = 1.05) and a high significance was observed (*p* \< 0.005), suggesting that age may have a minor negative impact on the survival of patients with proneural GBM. The opposite results were observed in patients with classical subtype GBM, wherein the expression HR was higher than 1 (HR = 2.531) and a moderate significance was reported (*p* \< 0.1). Interestingly, MGMT methylation was significantly more beneficial (HR = 4.67, *p* \< 0.05) than age (HR = 1.005) in this group.

![Cox proportional analysis of 422 patients with GBM from the TCGA database divided into subtypes based on *MuD* expression level, as analyzed with GBM Bio Discovery Portal for total GBM **(A)**, Classical subtype **(B)**, Neural subtype **(C)**, Proneural subtype **(D)** and Mesenchymal subtype **(E)**. Patients were ranked into four quartiles based on *MuD* expression level. The survival rate of the patients from the first quartile with the lowest ranked *MuD* expression was compared to that of the patients from the fourth quartile. Age and *MGMT* promoter methylation status were used as covariates. C, classical; M, mesenchymal; P, proneural; N, neural; QT, quartile.](fgene-10-00884-g003){#f3}

*MuD* Expression Correlated With That of *EXOC5*, *PPP2R2E*, and *SOS2* and *MuD* Overexpression Upregulated *PPP2R5E* and *SOS2* {#s3_5}
---------------------------------------------------------------------------------------------------------------------------------

We investigated the tumor-related genes in GBM tissues that showed correlation with *MuD* expression. Based on UALCAN results, we identified exocyst complex component 5 (*EXOC5*), protein phosphatase 2 regulatory subunit B'Epsilon (*PPP2R5E*), and son of sevenless homolog 2 (*SOS2*) to exhibit high correlations with *MuD* expression in GBM tumors from TCGA patients (Pearson's correlation coefficient \> 0.79) ([**Figure 4A**](#f4){ref-type="fig"}). Patient survival data based on *EXOC5*, *PPP2R5E*, and *SOS2* expression levels were available in the TCGA-GBM database, and the analysis with Cox proportional hazard model revealed that the high expression levels of these genes were associated with high survival in patients with proneural GBM at a log-rank *P* value cutoff of 0.05 (*PP2R5E* and *SOS2*) or close to 0.05 (*EXOC5*) ([**Supplementary Figure 4**](#SM1){ref-type="supplementary-material"}). Correlation in BRCA, KIRC, LUAD, ESCA, and CHOL were also displayed as a table for the upmost linked 10 genes ([**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}). EXOC5 shows high correlation with MuD in all subtypes except KIRC. To further investigate the correlation between *MuD* and these genes, we used a GBM cell line, U251-MG, a CRISPR-Cas9-generated *MuD* KO line β18, a plasmid transfection line containing pEGFP-C1 (C1), and a line SE *MuD* following MuD-GFP-C1 transfection (C1MuD). Although *MuD* KO failed to affect the expression of *EXOC5*, *PPO2R5E*, and *SOS2*, *MuD* stable expression increased *PPP2R5E* and *SOS2* expression levels to some extent ([**Figure 4B**](#f4){ref-type="fig"}). The expression of these genes was also investigated in the biospecimens mentioned below, but the Pearson's correlation coefficient was insignificant, probably owing to the small sample number ([**Supplementary Figure 5**](#SM1){ref-type="supplementary-material"}).

![Correlation between *EXOC5*, *PPP2R5E*, and *SOS2* expression levels and *MuD* levels. Expression in GBM tissues from TCGA database **(A)** and expression of *MuD*, *EXOC5*, *PPP2R5E*, and *SOS2* in the GBM *MuD* KO line β18 and *MuD* overexpression line C1MuD as compared with that in their respective controls **(B)**.](fgene-10-00884-g004){#f4}

Correlation Analysis Suggested the Possible Interactions Between *MuD* and Other Proteins That Affected Prognosis in Patients With GBM {#s3_6}
--------------------------------------------------------------------------------------------------------------------------------------

To examine the network of proteins that potentially interact with MuD, we used STRING ([@B50]) ([**Figure 5**](#f5){ref-type="fig"}). The identified interactors were found to be other components of the AP complexes. Survival data were unavailable for the identified proteins, AP5B1, AP5S1, AP5Z1 (other putative components of the fifth AP complex) and AP4B1 and AP4S1 (components of the fourth AP complex). The components of the fourth AP complex showed opposite patterns in terms of survival and MuD expression, as the first quartile patients with AP4M1 had higher chances of survival. Another component of the fourth complex, AP4E1 showed a similar pattern with MuD in proneural subclass but revealed a different pattern in the mesenchymal subclass, wherein survival chance was highly correlated with the fourth quartile patients of AP4E1. Components of the first AP complex (AP1G2 and AP1S1) as well as the third (AP3S2) and fourth (AP4S1) complexes showed no correlation between expression and survival in patients with proneural GBM ([**Supplementary Figure 6**](#SM1){ref-type="supplementary-material"}). This discrepancy among components of similar complexes suggests the possibility of additional roles of MuD aside from its involvement with the component of AP5. BioGrid ([@B9]) shows that besides other AP complex subunits, DDB1 and CUL4-associated factor 4 (DCAF4), spatacsin vesicle trafficking-associated (SPG11), general transcription factor IIIC subunit 3 (GTF3C3), and paired box protein PAX-6 (PAX6) are candidate protein interactors for MuD in human cells. Further investigation is warranted to validate the interactions of these components with MuD.

![Analysis of candidate proteins interacting with MuD. STRING analysis showing interactions between MuD (AP5M1) and other adaptor protein complex subunits **(A)**. BioGRID analysis revealing the additional putative MuD interacting proteins **(B)**.](fgene-10-00884-g005){#f5}

Expression Analysis Revealed Putative Post-Translational Regulation of *MuD* {#s3_7}
----------------------------------------------------------------------------

To investigate MuD expression patterns in human brain tumor tissues, we isolated RNA and protein from six tumor biospecimens (four GBMs, one oligodendroglioma, and one ependymoma) and matched normal tissues ([**Table 2**](#T2){ref-type="table"}). Of these, four pairs exhibited MuD upregulation in the tumors as compared with that in the matched normal tissues, with high significance in three samples ([**Figure 6A**](#f6){ref-type="fig"}, lane 3, 4, and 6). Two additional GBM samples ([**Figure 4B**](#f4){ref-type="fig"}, lanes 7 and 9) and oligodendroglioma and ependymoma samples ([**Figure 6B**](#f6){ref-type="fig"}, lanes 11, and 12) showed higher MuD expression than normal tissues. These findings imply that MuD expression may be upregulated in brain tumors, at least in GBM and other glioma tissues. Interestingly, neither MuD mRNA and protein levels nor subtypes showed any significant correlation, as MuD was only upregulated in patient 5 ([**Figure 7A**](#f7){ref-type="fig"}). All but one (NEFL) subtype marker showed upregulation in patient 5 ([**Figure 7B**](#f7){ref-type="fig"}) as compared with that in the other patients ([**Figure 7C**](#f7){ref-type="fig"}), suggestive of the possible failure of gene downregulation in the tumor from this patient. As MuD protein expression was upregulated in at least four patients, there is a possibility of putative post-translational control of MuD in brain tumors without ruling out the chances of contamination from neighboring tissues.

###### 

Clinical characteristics of patients with brain tumor in this study. GB, glioblastoma; ODG, oligodendroglioma; ED, ependymoma.

  Patients   Tissue        Tissue bcode   Diagnosis   WHO grade   Age      Gender   Tissue   Comment
  ---------- ------------- -------------- ----------- ----------- -------- -------- -------- ----------------------------
  1          ANC-13-0005   25502083       GB          4           81--85   Male     Pair     High necrosis rate
  2          ANC-13-0028   25502722       GB          4           81--85   Female   Pair     --
  3          ANC-13-0018   25680967       GB          4           61--65   Female   Pair     --
  4          ANC-13-0019   25371685       GB          4           61--65   Male     Pair     --
  5          ANC-13-0027   25333994       GB          4           71--75   Female   Pair     --
  6          ANC-13-0052   25072638       GB          4           56--60   Female   Pair     --
  7          ANC-13-0014   25502189       GB          4           71--75   Male     Tumor    --
  8          ANC-13-0022   25502458       GB          4           76--80   Female   Tumor    --
  9          ANC-14-0032   25756981       GB          4           41--45   Male     Tumor    --
  10         ANC-15-0009   25227244       GB          4           56--60   Male     Tumor    --
  11         ANC-14-0041   25537678       ODG         2           36--40   Female   Tumor    Low tumor cells percentage
  12         ANC-15-0061   25022741       ED          2           51--55   Female   Tumor    --

![Immunoblot analysis of MuD expression in six pairs of GBM **(A)** and GBM and astrocytoma biospecimens **(B)**. N, normal tissue; T, tumor tissue \**p* \< 0.01, \*\**p* \< 0.005, \*\*\**p* \< 0.001.](fgene-10-00884-g006){#f6}

![Rt-qPCR analysis of *MuD* and subtypes marker genes expression. Expression of *MuD* mRNA analyzed with RT-qPCR in patient tissues across GBM and astrocytoma brain tumor tissues **(A)**. Expression of subtype markers in tissues from patient 5 **(B)** and other patients expression of subtype markers **(C)**. mRNA expression was normalized to *GAPDH* levels (\**p* \< 0.05).](fgene-10-00884-g007){#f7}

Discussion {#s4}
==========

*MuD* was identified in a screening approach aimed to reveal any novel genes involved in Fas-mediated apoptosis ([@B31]). *MuD* plays a specific role in several cancer cells ([@B34]; [@B12]), and is thought to exert its functions through apoptotic signaling, considering its cleavage by active caspase-3 upon TRAIL stimulation ([@B46]). However, the detailed roles of *MuD* in tumors remain to be elucidated. Herein, our findings based on the careful analyses of both metadata and data from patients with brain tumor suggest that any alterations in *MuD* expression could be associated with tumor progression and survival in selected cancer types.

We used two web-based portals to evaluate the potential role of *MuD* in cancer. Although the key data source for both UALCAN and GEPIA data is TCGA, only two cancer types were detected in both portals, including KRIC and ESCA. This discrepancy between the two portals may be related to the different data processing method or owing to the use of additional data from MET500 and GTEx projects, respectively. Although more cancer types were found to exhibit *MuD* upregulation in tumors using GTEx, UALCAN was more prone to detect cancer types and survival correlation with *MuD* downregulation. This result may be partially attributed to the fact that GTEx projects collected more samples, including healthy tissue data, for most cancer types, whereas both MET500 and GTEx projects had no data on patient survival. As a consequence, drastic changes in *p* and log-rank values were reported. Nevertheless, we identified two cancer types, wherein *MuD* may exhibit a role in tumor development and serve as a potential biomarker. Our results also demonstrate that although large-scale data analysis may be useful in finding novel oncogenes and new biomarkers, the data should be carefully validated.

In a previous study, we reported the anti-apoptotic function of *MuD* in GBM cell lines ([@B12]) and investigated the correlation between *MuD* expression and cancer progression. We failed to observe any correlation between *MuD* expression and overall survival in patients with GBM. However, GEPIA analysis suggested the upregulation of *MuD* in GBM tumors, and MuD protein levels were markedly upregulated in human brain tumor tissues, including 10 GBMs. *MuD* mRNA level from the same tissues showed no correlation except one at *p* \< 0.05. Although this observation may be related to the small number of biospecimens investigated, additional regulation of *MuD* may occur at the post-translational level. This hypothesis is consistent with our previous finding that MuD was downregulated following TRAIL stimulation without any alteration in the *MuD* mRNA level ([@B12]).

Proneural GBM differs from other GBM subgroups with respect to gene expression patterns and responses to drug treatment ([@B11]). The proneural GBM cohort showed significantly improved prognosis as compared with patients with other subtypes ([@B54]) but failed to respond to immunotherapy as efficiently as the mesenchymal GBM cohort, presumably owing to TGF-R2 deficiency ([@B3]). Our findings showed that higher MuD expression levels were associated with prolonged survival in patients with proneural GBM; however, this correlation could not be extended to all patients with GBM. Although we failed to notice any correlation between GBM subtypes and MuD expression in our biospecimens, probably owing to the small sample size and the markers investigated, *MuD* expression might exert differential effects based on GBM subtypes and *MuD* may serve as a potential target gene specifically for the treatment of proneural subtype.

Analyses of MuD protein level, localization, and interactions with other putative proteins suggest its importance as a component of the putative AP5 complex ([@B23]). Clathrin AP complexes play crucial roles in protein sorting in diverse post-Golgi pathways and are involved in endocytosis ([@B37]). In particular, the AP1 complex is involved in trafficking between the trans-Golgi network (TGN) and endosomes ([@B24]), AP2 is associated with endocytosis ([@B37]), and AP3 mediates trafficking between the TGN/endosome and the vacuole/lysozyme system ([@B16]). AP4 was thought to play a role in vacuolar sorting in plant cells ([@B22]) and interact with Tepsin ([@B20]). AP complexes are involved in several diseases, including X-linked mental retardation ([@B52]), Alzheimer's disease ([@B4]), and Hermansky--Pudlak syndrome ([@B17]). Whereas these complexes showed no correlation with MuD, the two putative partner proteins of MuD, AP4M1, and AP4E1, are components of the AP4 complex and showed correlation with cancer prognosis. A recent report showed that AP4 promotes oncogenic phenotype and drug resistance in breast cancer through the regulation of a novel oncogene, lysosomal-associated protein transmembrane-4 beta (*LAPTM4B*) ([@B57]), and induces prostate cancer proliferation though l-plastin regulation ([@B10]). These studies suggest that AP complexes may play a role in cancer cell proliferation.

Aside from its role as a component of the AP5 complex, MuD is involved in cancer pathogenesis ([@B38]; [@B29]; [@B15]). MuD is implicated in TRAIL-induced apoptosis signaling ([@B34]; [@B46]; [@B12]). Studies have shown BID and Bcl2 as molecules acting upstream and downstream of MuD, respectively ([@B12]), suggesting that MuD may perform a novel role in the cancer apoptotic pathway. Our analysis identified several candidate genes, including *EXOC5*, *PPP2R5E*, and *SOS2*, and showed that *PPP2R5E* and *SOS2* expression levels correlated with MuD level in tumor cells to some extent. We failed to detect any correlation between *MuD* and *EXOC5* expression; however, *EXOC5* is adjacent to *MuD* (*EXOC5* 5′-UTR starts at Chr14: 57,268,899 and *MuD* 5′-UTR starts at Chr14: 57,268,888). As *MuD* KO or stable expression showed no effect on *EXOC5* expression, there is a possibility that the correlation between *EXOC5* and *MuD* expression may be related to the positional effect. A previous study using a KO mouse model showed that the deletion of *EXOC5* led to apoptosis and disorganization of hair cell stereocilia bundles ([@B33]). *PPPR2RE* is known as a tumor suppressor gene, and its downregulation induces growth inhibition and apoptosis in gastric cancer cells ([@B36]). *SOS2* encodes a Ras-specific guanine nucleotide exchange factor ([@B19]), and its downregulation decreases the level of Ras and activation of MAP kinase kinase1/2 (MEKK1/2), ultimately inhibiting TNFα-induced apoptosis ([@B32]). Not only *PPP2R5E* and *SOS2* expression levels slightly correlated with that of *MuD* in GBM cell lines but also high expression of these genes was associated with longer survival among patients with proneural GBM at a moderate level ([**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}). Further study to validate the involvement of these genes in tumor generation linked to *MuD* is in progress.

Based on the database analyses, we propose that *MuD* expression may be upregulated in ESCA and downregulated in KIRC. Further studies should carefully validate these results to evaluate *MuD* as a biomarker with a putative prognostic role. In addition, *MuD* may play a role in the survival of patients with proneural GBM and could be linked to candidate gene regulation. Taken together, our study suggests a novel role for *MuD* in cancer.
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